{"id":44609,"date":"2025-10-27T22:43:59","date_gmt":"2025-10-27T14:43:59","guid":{"rendered":"https:\/\/flcube.com\/?p=44609"},"modified":"2025-10-27T22:44:00","modified_gmt":"2025-10-27T14:44:00","slug":"chiesi-group-launches-first-eb-wound-treatment-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44609","title":{"rendered":"Chiesi Group Launches First EB Wound Treatment in China"},"content":{"rendered":"\n

The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.<\/p>\n\n\n\n

Disease Background<\/strong>
Epidermolysis Bullosa (EB), a rare disease with an estimated 15,000 patients in China, is caused by inherited factors or gene mutations. It is characterized by fragile skin that blisters or erodes easily. The launch of FILSUVEZ in Lecheng (Boao) addresses the previous treatment gap in China, offering an advanced therapeutic option for EB patients.<\/p>\n\n\n\n

Product Benefits<\/strong>
FILSUVEZ meets clinical needs by increasing target wound closure rates, shortening healing time, reducing target wound area, decreasing dressing change frequency, alleviating pain during dressing changes, and reducing wound care time for patients and caregivers.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
In the largest global, multi-center, randomized controlled Phase III clinical trial for EB, the birch triterpenes treatment group showed a 44% higher probability of achieving complete target wound closure within 45 days compared to the control gel group. The average time to target wound closure was shortened by 6.8 days.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative…<\/p>\n","protected":false},"author":1,"featured_media":44612,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[91,1919,24],"class_list":["post-44609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boao-lecheng-pilot-zone","tag-chiesi-farmaceutici","tag-rare-orphan-disease-drugs"],"yoast_head":"\nChiesi Group Launches First EB Wound Treatment in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44609\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chiesi Group Launches First EB Wound Treatment in China\" \/>\n<meta property=\"og:description\" content=\"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44609\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T14:43:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T14:44:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chiesi Group Launches First EB Wound Treatment in China\",\"datePublished\":\"2025-10-27T14:43:59+00:00\",\"dateModified\":\"2025-10-27T14:44:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2709.webp\",\"keywords\":[\"Boao Lecheng pilot zone\",\"Chiesi Farmaceutici\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44609#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44609\",\"name\":\"Chiesi Group Launches First EB Wound Treatment in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2709.webp\",\"datePublished\":\"2025-10-27T14:43:59+00:00\",\"dateModified\":\"2025-10-27T14:44:00+00:00\",\"description\":\"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44609\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2709.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2709.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chiesi Group Launches First EB Wound Treatment in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44609#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chiesi Group Launches First EB Wound Treatment in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chiesi Group Launches First EB Wound Treatment in China - Insight, China's Pharmaceutical Industry","description":"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44609","og_locale":"en_US","og_type":"article","og_title":"Chiesi Group Launches First EB Wound Treatment in China","og_description":"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.","og_url":"https:\/\/flcube.com\/?p=44609","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T14:43:59+00:00","article_modified_time":"2025-10-27T14:44:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44609#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44609"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chiesi Group Launches First EB Wound Treatment in China","datePublished":"2025-10-27T14:43:59+00:00","dateModified":"2025-10-27T14:44:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44609"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44609#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","keywords":["Boao Lecheng pilot zone","Chiesi Farmaceutici","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44609#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44609","url":"https:\/\/flcube.com\/?p=44609","name":"Chiesi Group Launches First EB Wound Treatment in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44609#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44609#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","datePublished":"2025-10-27T14:43:59+00:00","dateModified":"2025-10-27T14:44:00+00:00","description":"The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world\u2019s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44609#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44609"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44609#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","width":1080,"height":608,"caption":"Chiesi Group Launches First EB Wound Treatment in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44609#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chiesi Group Launches First EB Wound Treatment in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2709.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44609"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44609\/revisions"}],"predecessor-version":[{"id":44613,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44609\/revisions\/44613"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44612"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}